科伦药业
(002422)
| 流通市值：573.96亿 | | | 总市值：703.13亿 |
| 流通股本：12.99亿 | | | 总股本：15.91亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 13,112,749,782 | 8,838,531,817 | 4,259,244,936 | 18,512,918,907 |
| 营业收入 | 13,112,749,782 | 8,838,531,817 | 4,259,244,936 | 18,512,918,907 |
| 二、营业总成本 | 12,001,794,511 | 8,121,411,562 | 3,990,126,052 | 16,435,765,003 |
| 营业成本 | 6,898,055,352 | 4,634,070,041 | 2,329,222,978 | 9,655,237,375 |
| 税金及附加 | 189,456,807 | 133,094,071 | 70,650,188 | 257,850,170 |
| 销售费用 | 2,354,520,751 | 1,552,619,715 | 722,545,460 | 3,039,399,543 |
| 管理费用 | 835,554,450 | 549,453,457 | 269,857,187 | 1,206,565,999 |
| 研发费用 | 1,685,334,557 | 1,212,595,045 | 586,142,349 | 2,205,212,429 |
| 财务费用 | 38,872,594 | 39,579,233 | 11,707,890 | 71,499,487 |
| 其中:利息费用 | 68,297,068 | 47,829,607 | 23,116,294 | 102,836,710 |
| 其中:利息收入 | 39,357,913 | 23,928,450 | 13,480,148 | 81,421,100 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 35,076,178 | 18,418,112 | 7,195,352 | 27,611,838 |
| 加:投资收益 | 152,509,704 | 110,371,272 | 62,930,070 | 210,412,627 |
| 资产处置收益 | -2,549,352 | 1,285,491 | 1,154,694 | 5,320,176 |
| 资产减值损失(新) | -57,104,571 | -57,104,571 | 0 | -116,224,608 |
| 信用减值损失(新) | -27,358,169 | -24,350,282 | -13,733,534 | -23,501,166 |
| 其他收益 | 177,383,276 | 131,471,295 | 29,826,011 | 340,276,895 |
| 四、营业利润 | 1,388,912,337 | 897,211,572 | 356,491,477 | 2,521,049,666 |
| 加:营业外收入 | 711,094,602 | 708,097,953 | 101,292,643 | 80,913,387 |
| 减:营业外支出 | 120,875,375 | 52,124,533 | 16,735,911 | 198,127,465 |
| 五、利润总额 | 1,979,131,564 | 1,553,184,992 | 441,048,209 | 2,403,835,588 |
| 减:所得税费用 | 204,496,334 | 126,922,427 | -31,652,065 | 526,624,380 |
| 六、净利润 | 1,774,635,230 | 1,426,262,565 | 472,700,274 | 1,877,211,208 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,774,635,230 | 1,426,262,565 | 472,700,274 | 1,877,211,208 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,467,027,147 | 1,127,768,264 | 453,700,712 | 1,701,935,493 |
| 少数股东损益 | 307,608,083 | 298,494,301 | 18,999,562 | 175,275,715 |
| 扣除非经常损益后的净利润 | 1,061,166,108 | 699,366,733 | 381,454,885 | 1,596,533,268 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.92 | 0.71 | 0.29 | 1.07 |
| (二)稀释每股收益 | 0.92 | 0.71 | 0.29 | 1.07 |
| 八、其他综合收益 | -59,083,295 | -39,307,445 | -57,105,201 | -51,730,405 |
| 归属于母公司股东的其他综合收益 | -61,154,625 | -34,988,915 | -56,715,392 | -49,434,285 |
| 九、综合收益总额 | 1,715,551,935 | 1,386,955,120 | 415,595,073 | 1,825,480,803 |
| 归属于母公司股东的综合收益总额 | 1,405,872,522 | 1,092,779,349 | 396,985,320 | 1,652,501,208 |
| 归属于少数股东的综合收益总额 | 309,679,413 | 294,175,771 | 18,609,753 | 172,979,595 |
| 公告日期 | 2026-10-29 | 2026-08-27 | 2026-04-29 | 2026-04-03 |
| 审计意见(境内) | | | | 标准无保留意见 |